SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Gregersen Niels)
 

Search: WFRF:(Gregersen Niels) > Bortezomib consolid...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006371naa a2200769 4500
001oai:DiVA.org:liu-96994
003SwePub
008130902s2013 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:2a02bd7c-2f3a-4e13-99b8-394c86a11999
009oai:DiVA.org:uu-223033
009oai:prod.swepub.kib.ki.se:127146949
009oai:DiVA.org:umu-79913
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-969942 URI
0247 a https://doi.org/10.1182/blood-2012-11-4645032 DOI
0247 a https://lup.lub.lu.se/record/40432012 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2230332 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1271469492 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-799132 URI
040 a (SwePub)liud (SwePub)lud (SwePub)uud (SwePub)kid (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Mellqvist, Ulf-Henriku Sahlgrens University Hospital, Sweden4 aut
2451 0a Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
264 1b American Society of Hematology,c 2013
338 a print2 rdacarrier
500 a Funding Agencies|Johnson Johnson||Nordic Cancer Union||Boras foundation for cancer research||
520 a The Nordic Myeloma Study Group conducted an open randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients with newly diagnosed multiple myeloma. Overall, 370 patients were centrally randomly assigned 3 months after ASCT to receive 20 doses of bortezomib given during 21 weeks or no consolidation. The hypothesis was that consolidation therapy would prolong progression-free survival (PFS). The PFS after randomization was 27 months for the bortezomib group compared with 20 months for the control group (P = .05). Fifty-one of 90 patients in the treatment group compared with 32 of 90 controls improved their response after randomization (P = .007). No difference in overall survival was seen. Fatigue was reported more commonly by the bortezomib-treated patients in self-reported quality-of-life (QOL) questionnaires, whereas no other major differences in QOL were recorded between the groups. Consolidation therapy seemed to be beneficial for patients not achieving at least a very good partial response (VGPR) but not for patients in the andgt;= VGPR category at randomization. Consolidation with bortezomib after ASCT in bortezomib-naive patients improves PFS without interfering with QOL. This trial was registered at www.clinicaltrials.gov as #NCT00417911.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a MEDICINE
653 a MEDICIN
7001 a Gimsing, Peteru Rigshosp, Denmark4 aut
7001 a Hjertner, Oyvindu Norwegian University of Science and Technology, Norway4 aut
7001 a Lenhoff, Stigu Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital, Sweden4 aut0 (Swepub:lu)med-slf
7001 a Laane, Edwardu North Estonian Regional Hospital, Estonia4 aut
7001 a Remes, Kariu Turku University, Finland4 aut
7001 a Steingrimsdottir, Hlifu Landspitali University Hospital, Iceland4 aut
7001 a Abildgaard, Nielsu Odense University Hospital, Denmark4 aut
7001 a Ahlberg, Luciau Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Hematologiska kliniken US4 aut0 (Swepub:liu)lucah64
7001 a Blimark, Cecilieu Sahlgrens University Hospital, Sweden4 aut
7001 a Dahl, Inger Marieu University of North Norway, Norway4 aut
7001 a Forsberg, Karinu Umeå universitet,Patologi,Norrlands University Hospital, Sweden4 aut0 (Swepub:umu)nonkin02
7001 a Gedde-Dahl, Tobiasu Oslo University Hospital, Norway4 aut
7001 a Gregersen, Henriku Aalborg Hospital, Denmark4 aut
7001 a Gruber, Astridu Karolinska Institute, Sweden4 aut
7001 a Guldbrandsen, Ninau Oslo University Hospital, Norway4 aut
7001 a Haukas, Einaru Stavanger University Hospital, Norway4 aut
7001 a Carlson, Kristinau Uppsala universitet,Hematologi,Akad University Hospital, Sweden4 aut0 (Swepub:uu)krica965
7001 a Kvam, Ann Kristinu Oslo University Hospital, Norway4 aut
7001 a Nahi, Harethu Karolinska Institutet,Karolinska Institute, Sweden4 aut
7001 a Lindas, Roaldu Haukeland Hospital, Norway4 aut
7001 a Frost Andersen, Nielsu Aarhus University Hospital, Denmark4 aut
7001 a Turesson, Ingemaru Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital, Sweden4 aut0 (Swepub:lu)medf-itu
7001 a Waage, Andersu Norwegian University of Science and Technology, Norway4 aut
7001 a Westin, Janu Sahlgrens University Hospital, Sweden4 aut
7102 a Sahlgrens University Hospital, Swedenb Rigshosp, Denmark4 org
7730 t Bloodd : American Society of Hematologyg 121:23, s. 4647-4654q 121:23<4647-4654x 0006-4971x 1528-0020
8564 u https://ashpublications.org/blood/article-pdf/121/23/4647/1366249/4647.pdf
8564 u http://dx.doi.org/10.1182/blood-2012-11-464503x freey FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-96994
8564 8u https://doi.org/10.1182/blood-2012-11-464503
8564 8u https://lup.lub.lu.se/record/4043201
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-223033
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:127146949
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-79913

Find in a library

  • Blood (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view